Neurology

DEA Reschedules Cannabidiol, Paving the Way to Market

The US Drug Enforcement Administration has moved the FDA-approved cannabis-based drug for Lennox-Gastaut syndrome and Dravet syndrome from Schedule I to V, concluding that it has a low potential for abuse.
Medscape Medical News

Source link

Related posts

DO THE MARKS IN AN EXAMINATION REALLY MATTER A LOT?

Newsemia

Spotlight on the February 26 issue

Newsemia

Patent foramen ovale and cryptogenic stroke: diagnosis and updates in secondary stroke prevention.

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World